Is sofosbuvir and velpatasvir (Epclusa) the third generation?

Sofosbuvir and velpatasvir (Epclusa) combination, also known as the third generation of Epclusa, is suitable for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection. It is also suitable for the treatment of patients without cirrhosis or compensated cirrhosis, and patients with decompensated cirrhosis in combination with ribavirin. Before using sofosbuvir-velpatasvir combination, all patients need to be tested for evidence of current or previous hepatitis B virus (HBV) infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).